Total Payments
$56,311
2024 Payments
$1,561
Companies
13
Transactions
67
Medicare Patients
987
Medicare Billing
$299,209
Payment Breakdown by Category
Consulting$43,585 (77.4%)
Research$7,311 (13.0%)
Travel$3,926 (7.0%)
Food & Beverage$1,480 (2.6%)
Education$7.98 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $43,585 | 23 | 77.4% |
| Unspecified | $7,311 | 3 | 13.0% |
| Travel and Lodging | $3,926 | 12 | 7.0% |
| Food and Beverage | $1,480 | 26 | 2.6% |
| Education | $7.98 | 3 | 0.0% |
Payments by Type
General
$49,000
64 transactions
Research
$7,311
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $20,500 | 18 | $0 (2020) |
| Janssen Scientific Affairs, LLC | $11,903 | 14 | $0 (2019) |
| Ardelyx, Inc. | $7,311 | 3 | $0 (2022) |
| AKEBIA THERAPEUTICS INC | $6,235 | 1 | $0 (2019) |
| Relypsa, Inc. | $3,926 | 6 | $0 (2018) |
| Keryx Biopharmaceuticals, Inc. | $3,700 | 1 | $0 (2017) |
| CSL Behring | $1,556 | 6 | $0 (2024) |
| Otsuka Pharmaceutical Co., Ltd. | $716.32 | 8 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $155.38 | 4 | $0 (2022) |
| Alexion Pharmaceuticals, Inc. | $132.35 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,561 | 8 | CSL Behring ($1,556) |
| 2023 | $135.01 | 2 | Alexion Pharmaceuticals, Inc. ($132.35) |
| 2022 | $7,579 | 8 | Ardelyx, Inc. ($7,311) |
| 2020 | $11,000 | 8 | Merck Sharp & Dohme Corporation ($11,000) |
| 2019 | $16,094 | 14 | AKEBIA THERAPEUTICS INC ($6,235) |
| 2018 | $13,176 | 19 | Janssen Scientific Affairs, LLC ($6,099) |
| 2017 | $6,765 | 8 | Keryx Biopharmaceuticals, Inc. ($3,700) |
All Payment Transactions
67 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/07/2024 | CSL Behring | — | Travel and Lodging | In-kind items and services | $724.32 | General |
| 05/07/2024 | CSL Behring | — | Travel and Lodging | In-kind items and services | $332.24 | General |
| 05/07/2024 | CSL Behring | — | Travel and Lodging | In-kind items and services | $177.27 | General |
| 05/07/2024 | CSL Behring | — | Food and Beverage | In-kind items and services | $95.00 | General |
| 05/07/2024 | CSL Behring | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 05/06/2024 | CSL Behring | — | Travel and Lodging | In-kind items and services | $177.27 | General |
| 03/12/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $2.66 | General |
| 01/22/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $2.66 | General |
| 11/06/2023 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $2.66 | General |
| 05/12/2023 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $132.35 | General |
| 05/17/2022 | Ardelyx, Inc. | — | — | Cash or cash equivalent | $993.50 | Research |
| Study: TEN-02-402 | ||||||
| 05/16/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $53.68 | General |
| 05/16/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $49.44 | General |
| 05/16/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $29.66 | General |
| 05/16/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $22.60 | General |
| 03/08/2022 | Ardelyx, Inc. | — | — | Cash or cash equivalent | $1,442.50 | Research |
| Study: TEN-02-402 | ||||||
| 01/27/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $112.74 | General |
| Category: Cardio-renal | ||||||
| 01/05/2022 | Ardelyx, Inc. | — | — | Cash or cash equivalent | $4,875.00 | Research |
| Study: TEN-02-402 | ||||||
| 02/19/2020 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 02/11/2020 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 02/04/2020 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 01/29/2020 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 01/27/2020 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 01/22/2020 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 01/08/2020 | Merck Sharp & Dohme Corporation | STEGLATRO (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: ENDOCRINOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TEN-02-402 | Ardelyx, Inc. | $7,311 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 201 | 417 | $208,311 | $58,469 |
| 2022 | 7 | 180 | 428 | $241,586 | $72,758 |
| 2021 | 9 | 300 | 650 | $311,428 | $89,717 |
| 2020 | 9 | 306 | 617 | $285,710 | $78,265 |
Total Patients
987
Total Services
2,112
Medicare Billing
$299,209
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 17 | 115 | $118,604 | $34,129 | 28.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 57 | 112 | $23,569 | $7,434 | 31.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 37 | 61 | $18,336 | $5,897 | 32.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 31 | 31 | $18,085 | $4,445 | 24.6% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2023 | 12 | 40 | $11,320 | $2,580 | 22.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 18 | 27 | $10,289 | $2,002 | 19.5% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 18 | 20 | $5,783 | $1,217 | 21.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 11 | 11 | $2,325 | $766.37 | 33.0% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 16 | 136 | $137,369 | $43,067 | 31.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 37 | 80 | $25,730 | $7,178 | 27.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 52 | 113 | $25,172 | $7,041 | 28.0% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 12 | 25 | $20,920 | $6,564 | 31.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 29 | 29 | $17,963 | $5,019 | 27.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 19 | 19 | $8,248 | $2,228 | 27.0% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 15 | 26 | $6,184 | $1,661 | 26.9% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 16 | 97 | $90,986 | $30,611 | 33.6% |
| 90966 | Home dialysis services per month, patient 20 years of age or older | Office | 2021 | 12 | 78 | $61,308 | $20,188 | 32.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 88 | 201 | $48,240 | $12,500 | 25.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 63 | 130 | $44,590 | $10,937 | 24.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 49 | 49 | $32,683 | $7,491 | 22.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 30 | 33 | $14,916 | $3,764 | 25.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 17 | 32 | $11,456 | $2,524 | 22.0% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 14 | 19 | $4,598 | $1,178 | 25.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 11 | 11 | $2,651 | $523.14 | 19.7% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2020 | 11 | 96 | $88,254 | $23,974 | 27.2% |
About Dr. Daniel Weiner, MD
Dr. Daniel Weiner, MD is a Nephrology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1437251360.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Weiner, MD has received a total of $56,311 in payments from pharmaceutical and medical device companies, with $1,561 received in 2024. These payments were reported across 67 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($43,585).
As a Medicare-enrolled provider, Weiner has provided services to 987 Medicare beneficiaries, totaling 2,112 services with total Medicare billing of $299,209. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Boston, MA
- Active Since 09/01/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1437251360
Products in Payments
- STEGLATRO (Drug) $20,500
- INVOKANA (Drug) $11,958
- Veltassa (Drug) $3,926
- Auryxia (Drug) $3,700
- Kerendia (Drug) $112.74
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Boston
David Friedman, M.d, M.D
Nephrology — Payments: $20.3M
Nephrology $20.3M
Martin Pollak, Md, MD
Nephrology — Payments: $20.3M
Nephrology $20.3M
Dr. Dennis Ausiello, Md, MD
Nephrology — Payments: $4.4M
Nephrology $4.4M
Dr. Ajay Singh, Md, MD
Nephrology — Payments: $1.2M
Nephrology $1.2M
Dr. Leslie Fang, Md, MD
Nephrology — Payments: $795,357
Nephrology $795,357
Dr. Jean Francis, M.d, M.D
Nephrology — Payments: $217,413
Nephrology $217,413